{"filing":{"accession_number":"0001171843-26-004338","cik":"0001505065","ticker":"BRSYF","company_name":"Brainsway Ltd.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"f6k_062426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505065/000117184326004338/f6k_062426.htm"},"events":[{"id":14463,"run_id":12876,"accession_number":"0001171843-26-004338","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the \"largest real-world analysis\" to date in this patient population, strengthening the clinical evidence base for the company's technology.","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":11910,"accession_number":"0001171843-26-004338","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the \"largest real-world analysis\" to date in this patient population, strengthening the clinical evidence base for the company's technology.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:30:38.437106+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11910,"accession_number":"0001171843-26-004338","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the \"largest real-world analysis\" to date in this patient population, strengthening the clinical evidence base for the company's technology.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T11:30:38.437106+00:00","company_name":"Brainsway Ltd.","ticker":"BRSYF","filing_date":"2026-06-29"}]}